ClinicalTrials.gg
RecruitingNCT07437404Updated Feb 27, 2026

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

A Phase 3 interventional study of SCT800 prophylaxis and treatment for bleeding events in Haemophilia A, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to male participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Apr 2024, registered Feb 2026).
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
Up to 6 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
52nd of 80
36 · median 54
Started
2024
with 9 others
Phase 3
41 of 93
9 open now
Primary completion
2028-12
later than 32 of 38 live
Registered
86th of 93
by date
Lead sponsor
5 of 93
Sinocelltech Ltd.

Among the 93 studies in Hemophilia A with a site in China, this one is the 52nd largest by planned enrollment of the 80 interventional ones that give a count, is one of 10 that started in 2024, is one of 41 in phase 3, reaches primary completion later than 32 of the 38 other live ones, and was the 86th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: Up to 6 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.

Read the detailed description

SCT800 is a recombinant human coagulation factor VIII, which was on market in 2021 in China. The indication of SCT800 is prophylaxis and control of bleeding events in adult and children, and for the perioperative management of bleeding events. This study continued to evaluate the safety and efficacy of SCT800 in previously untreated patients with severe haemophilia A.

03

Conditions studied

  • Haemophilia A

Browse trials for

Keywords

  • SCT800
  • haemophilia A
  • previously untreated patients
04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects with severe hemophilia A (FVIII:C \< 1% in central laboratory tests)
  • previously untreated with pdFVIII/rFVIII, including marketed SCT800 (those who have previously used ≤5EDs of blood products such as cryoprecipitate or fresh frozen plasma are acceptable).
  • FVIII inhibitor negative
  • .

Exclusion criteria

Exclusion Criteria:

  • Known allergy to recombinant coagulation factor VIII concentrate or any ; known allergy to bovine, rodent or hamster bovine;
  • subjects with a history or family history of FVIII inhibitor formation;
  • Clinical liver function test (、AST) ≥ 5 or clinical kidney function test (BUN,Cr) ≥2 ULN;
  • Patients with other coagulation dysfunction diseases in addition to hemophilia A.
  • (INR) > 1.5.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    SCT800 prophylaxis and control of bleeding events

    For prophylaxis, 15-50 IU/kg SCT800 is intravenously. For control of bleeding events(BE), 10-20 IU/kg for mild BE, 15 -30IU/kg for moderate BE, 30-50IU/kg for severe BE.

    Drug: SCT800 prophylaxis and treatment for bleeding events

Interventions

  • DrugSCT800 prophylaxis and treatment for bleeding events

    For prophylaxis, 15-50 IU/kg SCT800 is intravenously. For control of bleeding events(BE), 10-20 IU/kg for mild BE, 15 -30IU/kg for moderate BE, 30-50IU/kg for severe BE.

06

What researchers measure

Primary outcomes

  1. Incidence of FVIII inhibitor

    The percentage of FVIII inhibitor measured by Nijmegen-Bethesda

    Time frame: up to 50-100 Exposure Days

Secondary outcomes

  1. The percentage of adverse events

    Time frame: up to 50-100 exposure days

  2. annualized bleeding rate

    Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25)

    Time frame: up to 50-100 exposure days

  3. annualized joint bleeding rate

    Annualized joint bleeding rate(AJBR) can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25).

    Time frame: up to 50-100 exposure days

  4. consumption of SCT800

    consumption of SCT800 per month and per year

    Time frame: up to 50-100 exposure days

  5. hemostatic effect of SCT800

    The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved).

    Time frame: up to 50-100 exposure days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2028, 56 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 56 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 27, 2026
StartActual
Apr 26, 2024
Primary completionEst.
Dec 26, 2028
CompletionEst.
Dec 26, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07437404
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 26, 2024
Primary completion
Dec 26, 2028 (estimated)
Completion
Dec 26, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Runhui Wu
Contact
wurunhuigcp@163.com
+86-13370115037

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion